Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-8236 Phase 1 study in healthy subjects and asthma patients
NCT03652038Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Nov 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TD-8236 in asthma (6 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Number, severity and type of treatment emergent adverse events (SAD) and Number, severity and type of treatment emergent adverse events (MAD). Started Nov 2018; status: completed.
02
Drugs
TD-8236
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03652038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652038.